Luxembourg, Luxembourg
Luxembourg, Luxembourg

Time filter

Source Type

Benson E.E.,Damar Research Scientists | Betsou F.,Integrated Biobank of Luxembourg | Fuller B.J.,University College London | Harding K.,Damar Research Scientists | Kofanova O.,Integrated Biobank of Luxembourg
Cryo-Letters | Year: 2013

Low temperatures are used routinely to preserve diverse biospecimens, genetic resources and nonviable or viable biosamples for medical and clinical research in hospital-based biobanks and nonmedical biorepositories, such as genebanks and culture, scientific, museum, and environmental collections. However, the basic knowledge underpinning preservation can sometimes be overlooked by practitioners who are unfamiliar with fundamental cryobiological principles which are more usually described in research literature rather than in quality and risk management documents. Whilst procedures vary, low temperature storage is a common requirement and reaching consensus as to how best it is applied could facilitate the entire biopreservation sector. This may be achieved by encouraging an understanding of cryoprotection theory and emphasizing the criticality of thermal events (glass transitions, ice nucleation, thawing) for sample integrity, functionality and stability. The objective of this paper is to inspire diverse biopreservation sectors to communicate more clearly about low temperature storage and, raise awareness of the importance of cryobiology principles to field newcomers and biopreservation practitioners, by considering how the principles may be translated into evidence-based guidelines for biobank and biorepository operations. © CryoLetters, businessoffice@cryoletters.org.


Fliniaux O.,University of Picardie Jules Verne | Gaillard G.,Biobanque de Picardie | Lion A.,University of Picardie Jules Verne | Cailleu D.,Plateforme Analytique | And 2 more authors.
Journal of Biomolecular NMR | Year: 2011

A blood pre-centrifugation delay of 24 h at room temperature influenced the proton NMR spectroscopic profiles of human serum. A blood pre-centrifugation delay of 24 h at 4°C did not influence the spectroscopic profile as compared with 4 h delays at either room temperature or 4°C. Five or ten serum freeze-thaw cycles also influenced the proton NMR spectroscopic profiles. Certain common in vitro preanalytical variations occurring in biobanks may impact the metabolic profile of human serum. © 2011 Springer Science+Business Media B.V.


Paggetti J.,Luxembourg Institute of Health | Haderk F.,German Cancer Research Center | Seiffert M.,German Cancer Research Center | Janji B.,Luxembourg Institute of Health | And 12 more authors.
Blood | Year: 2015

Exosomes derived from solid tumor cells are involved in immune suppression, angiogenesis, and metastasis, but the role of leukemia-derived exosomes has been less investigated. The pathogenesis of chronic lymphocytic leukemia (CLL) is stringently associated with a tumor-supportive microenvironment and a dysfunctional immune system. Here, we explore the role of CLL-derived exosomes in the cellular and molecular mechanisms by which malignant cells create this favorable surrounding. We show that CLL-derived exosomes are actively incorporated by endothelial and mesenchymal stem cells ex vivo and in vivo and that the transfer of exosomal protein and microRNA induces an inflammatory phenotype in the target cells, which resembles the phenotype of cancer-associated fibroblasts (CAFs). As a result, stromal cells show enhanced proliferation, migration, and secretion of inflammatory cytokines, contributing to a tumor-supportive microenvironment. Exosome uptake by endothelial cells increased angiogenesis ex vivo and in vivo, and coinjection of CLL-derived exosomes and CLL cells promoted tumor growth in immunodeficient mice. Finally, we detected α-smooth actin-positive stromal cells in lymph nodes of CLL patients. These findings demonstrate that CLL-derived exosomes actively promote disease progression by modulating several functions of surrounding stromal cells that acquire features of cancer-associated fibroblasts. © 2015 by The American Society of Hematology.


Carter A.,OnCore UK | Carter A.,National Cancer Research Institute | Betsou F.,Integrated Biobank of Luxembourg
Biopreservation and Biobanking | Year: 2011

Biobanking is recognized as a critical area requiring development if progress is to be made in identifying clinically useful markers of disease and disease progression, discovering new drug targets, and understanding the mechanisms of disease in cancer. Researchers continue to report that they are unable to obtain sufficient high-quality, well-annotated samples of diseased and control tissue, blood, and other biological materials. At the same time, funders of research, and especially funders of biobanks, are looking to obtain the best value from their investments in sample and data collection. There is a need to increase the availability to researchers of large numbers of high-quality, well-annotated samples of diseased and control tissue, blood, and other biological materials and, in this way, accelerate cancer research. To do this, samples need to be collected, processed, and stored in standardized ways that give assurance to researchers that they are fit for purpose. Quality assurance is an essential part of good science and this article describes how quality assurance is applied in cancer biobanking and discusses the need for internationally acceptable standards. © Copyright 2011, Mary Ann Liebert, Inc.


Betsou F.,Integrated Biobank of Luxembourg | Parida S.K.,Vaccine Grand Challenges Program | Guillerm M.,WHO Special Programme for Research and Training in Tropical Diseases WHO TDR
Tuberculosis | Year: 2011

Research for biomarkers supporting personalized medicine in infectious diseases is needed, especially for tuberculosis in which the existing toolbox does not yet address the public health priorities. Biobanks are essential infrastructures in this effort by collecting, authenticating and preserving human and/or bacterial specimens. A broad range of specimens should be collected prior to, during and following treatment, with a comprehensive characterisation of the sample donors and the samples themselves to accommodate the most recent technological platforms in biomarker research. This review explains current state-of-the-field biobanking practices in tuberculosis and suggests technical and managerial improvements to ensure long-term preservation and optimal use of the specimens. Open-access and certified biobanks are an essential component of a strategy supporting the development of drugs and diagnostic tests for both public health and personalised medicine. Biobanks have a role to play in the interaction between these two - not always compatible - approaches. © 2011 Elsevier Ltd. All rights reserved.


Letellier E.,University of Luxembourg | Schmitz M.,University of Luxembourg | Baig K.,University of Luxembourg | Beaume N.,University of Luxembourg | And 9 more authors.
British Journal of Cancer | Year: 2014

Background:Over the past years, some members of the family of suppressor of cytokine signalling (SOCS) proteins have emerged as potential tumour suppressors. This study aimed at investigating the clinical significance of SOCS proteins in colorectal carcinoma (CRC). Methods:We integrated publicly available microarray expression data on CRC in humans, analysed the expression pattern of SOCSs and assessed the predictive power of SOCS2 and SOCS6 for diagnostic purposes by generating receiver operating characteristic curves. Using laser microdissected patient material we assessed SOCS expression on RNA and protein levels as well as their methylation status in an independent CRC patient cohort. Finally, we investigated the prognostic value of SOCS2 and SOCS6.Results:The meta-analysis as well as the independent patient cohort analysis reveal a stage-independent downregulation of SOCS2 and SOCS6 and identify both molecules as diagnostic biomarkers for CRC. We demonstrate a different methylation pattern within the SOCS2 promoter between tumour tissue and normal control tissue in 25% of CRC patients. Furthermore, early CRC stage patients with low expression of SOCS2 display significantly shorter disease-free survival.Conclusions:Our data offers evidence that SOCS2 and SOCS6 levels are reduced in CRC and may serve as diagnostic biomarkers for CRC patients. © 2014 Cancer Research UK. All rights reserved.


Marshall J.,Ryerson University | Marshall J.,CRP Sante | Bowden P.,Ryerson University | Schmit J.C.,CRP Sante | Betsou F.,Integrated Biobank of Luxembourg
Clinical Proteomics | Year: 2014

Protein biomarkers offer major benefits for diagnosis and monitoring of disease processes. Recent advances in protein mass spectrometry make it feasible to use this very sensitive technology to detect and quantify proteins in blood. To explore the potential of blood biomarkers, we conducted a thorough review to evaluate the reliability of data in the literature and to determine the spectrum of proteins reported to exist in blood with a goal of creating a Federated Database of Blood Proteins (FDBP). A unique feature of our approach is the use of a SQL database for all of the peptide data; the power of the SQL database combined with standard informatic algorithms such as BLAST and the statistical analysis system (SAS) allowed the rapid annotation and analysis of the database without the need to create special programs to manage the data. Our mathematical analysis and review shows that in addition to the usual secreted proteins found in blood, there are many reports of intracellular proteins and good agreement on transcription factors, DNA remodelling factors in addition to cellular receptors and their signal transduction enzymes. Overall, we have catalogued about 12,130 proteins identified by at least one unique peptide, and of these 3858 have 3 or more peptide correlations. The FDBP with annotations should facilitate testing blood for specific disease biomarkers. © 2014 Marshall et al.; licensee BioMed Central Ltd.


Ammerlaan W.,Integrated Biobank of Luxembourg | Betsou F.,Integrated Biobank of Luxembourg
Biopreservation and Biobanking | Year: 2016

Blood microRNAs (miRNAs) are ideal biomarkers, and blood derivatives are often collected in the scope of miRNA research projects. However, knowledge of temporal variations of miRNAs in healthy individuals is lacking. In this study, miRNA variability was measured over a 1-year period in different blood derivatives, collected every 2-3 months from two healthy donors. There is a continuum of intraindividual temporal variability, with particularly stable (coefficient of variation [CV] <20%-30%) and particularly unstable (CV >100%-130%) miRNAs in serum, plasma, and specific white blood cell subpopulations. The temporal intraindividual variability of miRNAs should be taken into consideration in experimental design of biospecimen collections and validation of diagnostic biomarkers. © Copyright 2016, Mary Ann Liebert, Inc. 2016.


Mathay C.,Integrated Biobank of Luxembourg | Ammerlaan W.,Integrated Biobank of Luxembourg | Betsou F.,Integrated Biobank of Luxembourg
Biopreservation and Biobanking | Year: 2012

Buffy coat isolation from whole blood has typically been a long, manual process. We tested and evaluated the feasibility, efficiency, and reproducibility of extracting buffy coat by an automated process with the Tecan pipetting robot Freedom Evo200. © Copyright 2012, Mary Ann Liebert, Inc. 2012.


PubMed | Integrated Biobank of Luxembourg
Type: Journal Article | Journal: Biopreservation and biobanking | Year: 2016

Blood microRNAs (miRNAs) are ideal biomarkers, and blood derivatives are often collected in the scope of miRNA research projects. However, knowledge of temporal variations of miRNAs in healthy individuals is lacking. In this study, miRNA variability was measured over a 1-year period in different blood derivatives, collected every 2-3 months from two healthy donors. There is a continuum of intraindividual temporal variability, with particularly stable (coefficient of variation [CV] <20%-30%) and particularly unstable (CV >100%-130%) miRNAs in serum, plasma, and specific white blood cell subpopulations. The temporal intraindividual variability of miRNAs should be taken into consideration in experimental design of biospecimen collections and validation of diagnostic biomarkers.

Loading Integrated BioBank of Luxembourg collaborators
Loading Integrated BioBank of Luxembourg collaborators